Tumour Markers

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/19

flashcard set

Earn XP

Description and Tags

Vocabulary practice flashcards covering tumour marker definitions, historical milestones, clinical roles, classifications, specific diagnostic markers, and cut-off values based on the lecture by Dr. Eyam DSE.

20 Terms

1
New cards

Tumour markers

A group of proteins, hormones, enzymes, receptors, and other cellular products that are overexpressed by malignant cells or produced by the body in response to cancer growth, detectable in blood, urine, or tissue samples.

2
New cards

Bence-Jones protein

The first recognized tumour marker in historical medical practice.

3
New cards

Lead time

A characteristic of an ideal tumour marker denoting the interval of earlier detection or advance warning it provides compared to the standard clinical presentation.

4
New cards

Screening

The process of looking for cancer in individuals who have no symptoms of the disease.

5
New cards

Early detection

Finding cancer at an early stage when it is less likely to have spread and is easier to treat.

6
New cards

Her2/neu

A tumour marker that guides treatment by indicating therapy responsiveness; breast cancer patients positive for this marker are more likely to respond to Herceptin.

7
New cards

Ectopic hormone production

The production and secretion of hormones by tissues that do not normally synthesize them, occurring as a result of malignancy (e.g., ACTH or calcitonin).

8
New cards

Oncofetal antigens

The largest class of tumour markers, consisting of proteins coded by genes active during foetal development that function at low levels after birth but are reactivated by malignant tumours to produce high amounts of protein.

9
New cards

Alpha-fetoprotein (AFP)

A foetal glycoprotein used prenatally to detect spina bifida and CSF leakage; in non-pregnant adults, levels above 300 ng/L300\,\text{ng/L} suggest malignancy or liver disease, levels above 1000 ng/L1000\,\text{ng/L} almost always indicate cancer, and it is elevated in nearly all yolk sac tumours and 80%80\% of malignant liver tumours.

10
New cards

CA-125

A carbohydrate antigen marker used for the diagnosis, monitoring, and mass-correlation of ovarian cancer (elevated in approximately 75%75\% of cases overall, 50%50\% of Stage I, and 90%90\% of Stage II or higher), as well as 20%20\% of pancreatic cancers.

11
New cards

Carcinoembryonic antigen (CEA)

A cell membrane glycoprotein that reaches very high levels in colorectal cancer, is elevated in over 50%50\% of many carcinomas, and is monitored in plasma to assess whether second-look surgery should be performed.

12
New cards

Prostate specific antigen (PSA)

A small glycoprotein with protease activity specific for prostate tissue that is elevated in benign prostatic hypertrophy, prostatitis, and in more than 60%60\% of Stage A and 70%70\% of Stage B prostate cancers.

13
New cards

Free PSA

The portion of prostate specific antigen circulating unbound to protein in plasma; a low fraction in patients with a borderline total PSA of 4–10 ng/L4\text{--}10\,\text{ng/L} indicates a higher probability of prostate malignancy.

14
New cards

Oestrogen receptor (ER)

A nuclear receptor protein in breast and uterine tissues used to evaluate whether a breast cancer patient will respond to tamoxifen therapy, where levels greater than 10 fmol/mg protein10\,\text{fmol/mg protein} are considered positive.

15
New cards

Progesterone receptor (PR)

A marker consisting of two nuclear proteins in breast and uterine tissues; when co-positive with ER, patients have a greater than 60%60\% chance of tumour shrinkage with endocrine therapy, compared to less than 5%5\% if both are negative.

16
New cards

Human chorionic gonadotropin (hCG)

A glycoprotein produced by trophoblast cells and the developing placenta that serves as a tumour marker for choriocarcinoma, trophoblastic tumours, and approximately 60%60\% of testicular cancers.

17
New cards

Nuclear matrix protein (NMP22)

A structural nuclear protein released into the urine when bladder carcinoma cells die; it is positive in approximately 70%70\% of bladder carcinomas.

18
New cards

Bladder tumour-associated analytes (BTA)

A urinary marker comprised of type IV collagen, fibronectin, laminin, and proteoglycan, elevated in about 30%30\% of low-grade and over 60%60\% of high-grade bladder tumours.

19
New cards

Oncogenes (Tumour Markers)

Genes active during foetal development that trigger tumour growth upon activation in mature cells; their products include BRAC-1, myc, p53, RB gene, and Ph 1.

20
New cards

Second-look surgery

A repeat surgical intervention whose necessity is evaluated in patients by tracking serial plasma concentrations of carcinoembryonic antigen (CEA).